Drug intelligence / Profile preview

sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This product is a **combination vaccine** containing **Sabin-strain inactivated poliovirus vaccine (sIPV)** and **hepatitis A live attenuated vaccine**. - **Sabin-strain inactivated poliovirus vaccine (sIPV):** An inactivated (killed virus) vaccine derived from the attenuated Sabin strains of poliovirus, developed to provide immunity against poliomyelitis without the risk of vaccine-associated paralytic poliomyelitis. sIPV works by stimulating the immune system to produce neutralizing antibodies (IgG) against poliovirus types 1, 2, and 3[1][2][4][5]. The Sabin strains, originally developed for oral vaccines, are used inactivated in this formulation, reducing biosafety risks and avoiding transmission through fecal shedding[5]. - **Hepatitis A live attenuated vaccine:** A vaccine containing live, weakened hepatitis A virus that stimulates cellular and humoral immunity for long-term protection against hepatitis A infection. The vaccine is primarily indicated for **protection against both poliomyelitis and hepatitis A**. It is used in populations where combined prevention is needed, such as pediatric immunization programs.

02

Targets

Hepatitis A virus capsid protein

Beyond the preview

Go deeper on sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call